Background. Type 1 reaction (T1R) is an acute T-helper type 1 (Th1) inflammatory episode in patients with leprosy. While immunological responses associated with T1R have been investigated, the corresponding metabolic responses that could contribute to T1R pathology have received little attention.
Leprosy is a chronic infectious disease caused by Mycobacterium leprae and primarily affects skin and peripheral nerves. Despite effective multidrug therapy, this disease remains a public health problem in several countries where pockets of high endemicity exist [1] . Leprosy displays a spectrum of clinical forms associated with differences in host immune response and pathogen load [2] . At the tuberculoid pole, patients manifest a strong T-helper type 1 (Th1) response with a paucibacillary infection, while the lepromatous form is characterized by a weak or absent Th1 response and high bacterial load [2] . Patients with intermediate immune responses to M. leprae develop borderline clinical forms: borderline tuberculoid (BT), borderline borderline (BB), and borderline lepromatous (BL). Type 1 reaction (T1R) is a major complication in patients with a borderline clinical form and is characterized by an acute Th1-mediated inflammatory episode [3] . T1R can occur before, during, and after multidrug therapy and is the primary contributor to nerve damage. Delayed diagnosis of T1R contributes to the magnitude of nerve injury, and thus new diagnostic tools are needed to detect patients at risk of developing T1R [3] .
Many aspects of T1R immunopathogenesis remain unclear; however, it is well defined as a delayed-type hypersensitivity reaction, resulting from increased cell-mediated immunity to M. leprae antigens and the predominance of Th1 cytokines in T1R lesions [3, 4] . More recently, independent studies provided evidence that Th17 cells participate in T1R inflammatory response [5] [6] [7] . Transcriptional profiling supports the concept that adaptive and innate immune responses contribute to T1R [8, 9] and provide evidence for increased T-cell cytotoxicity and reduced regulation of T cells [6] . These findings shed light on immune cells, chemokines, cytokines, and transcriptional responses that underlie T1R; however, changes in secondary metabolites and, in particular, lipid mediators of inflammation have not been studied. It is well established that lipids derived from n-3 (or ω-3) and n-6 (or ω-6) polyunsaturated fatty acids (PUFAs) mediate inflammatory responses associated with innate and adaptive immunity [10, 11] . In the analysis of transcriptional profiles induced by an M. leprae antigen in patients with T1R, Orlova et al observed an increase in the transcript for cyclooxygenase-2 (COX-2), a key enzyme in the formation of n-6 and n-3 PUFA-derived lipid mediators [9] . Previous metabolomics studies also revealed altered PUFA metabolism in patients with leprosy free of a T1R [12, 13] . Based on these previous observations and the well-described role of individual lipid mediators [11, [14] [15] [16] [17] , we now hypothesize that the serum levels of lipid mediators associated with the induction or control of the inflammatory response will be altered in patients with leprosy who had T1R, compared with those without T1R.
To test our hypothesis, a semitargeted metabolomics approach using retrospective serum samples and a liquid chromatography-mass spectrometry (LC-MS) platform was used to assess whether PUFA metabolism and other metabolic pathways differed between the T1R and T1R-free groups among patients with leprosy. The data indicated that the greatest metabolic shifts occurred in arachidonic acid (AA), linoleic acid, and α-linolenic acid metabolism, all of which are PUFAs that are precursors of lipid mediators. Targeted analyses based on these findings revealed a significant shift in the serum levels of selected proinflammatory and proresolving lipid mediators.
METHODS

Clinical Samples
Retrospective serum samples from 7 patients with and 9 patients without T1R were obtained (Table 1) . Clinical forms of leprosy were classified on the basis of Ridley-Jopling criteria [2] . Detection of anti-phenolic glycolipid I (PGL-I) immunoglobulin M was performed [18] . T1R-free patients were examined for the absence of reactions (T1R and T2R) every 3 months for 3 years, and samples used for this study were only from patients who did not exhibit a reaction during follow-up. T1R was diagnosed when a patient had erythema, edema, and hypersensitivity of skin lesions sometimes accompanied by neuritis and/or edema of the hands, feet, and face. Plaques and small papules were observed in the skin of patients with T1R. T1R diagnoses were confirmed by histopathologic analysis. All patients (those with and those without T1R) were not receiving multidrug therapy or corticosteroid therapy at the time of blood collection. All individuals were recruited on a volunteer basis from the Leprosy Outpatient Unit (Oswaldo Cruz Foundation, Rio de Janeiro, Brazil). Written informed consent was obtained from all patients or, if the patient was a minor, from the patient's guardian. The institutional review boards of Colorado State University and the Oswaldo Cruz Foundation approved the use of sera for the reported study.
Metabolite Extraction and LC-MS
Metabolites were extracted from sera aliquots (80 μL) with methanol as described elsewhere [12] . We analyzed 20 μL of serum (via triplicate injections), using LC-MS on an Agilent system (Santa Clara, CA; Supplementary Methods). The order for the injection, including the triplicates, was randomized for LC-MS analyses.
Data Processing
Raw LC-MS data files were processed for peak detection, retention-time correction, and metabolite/molecular feature (MF) annotation, using XCMS [19] . Detailed methods and criteria for data normalization, MF selection, quantification, and statistical analyses are provided in the Supplementary Methods. Relative abundances of MFs (calculated as the log 2 of the MF peak area) were compared between patients with and those without T1R, using the R package limma, which implements a linear model algorithm and empirical Bayes adjustment to the t statistic [20, 21] . The P values were adjusted for false-discovery rate [22] . MFs that significantly (P < .05) differed between the T1R and T1R-free groups (log 2 fold changes ≥ 1.0) were selected for further identification.
Metabolite Identification
MFs were searched on the basis of their accurate mass (with an allowable error of 10 ppm) against the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (available at: http:// www.genome.jp/kegg/), using Pathos (available at: http:// motif.gla.ac.uk/Pathos/) [23] , and were assigned to putative structures in the context of metabolic pathways. Structures of putative metabolites were confirmed by LC-MS/MS through comparison with commercial standards (Supplementary Methods). 
Enzyme-Linked Immunoassay (EIA)
The measurement of resolvin D1 (RvD1), leukotriene B 4 (LTB 4 ), lipoxin A 4 (LXA 4 ), prostaglandin (PG) D 2 (PGD 2 ), and PGE 2 levels in individual sera was performed using EIA kits (Cayman Chemical) as previously described [13] . Samples from 7 healthy controls were included in the EIA, to acquire baseline concentrations of targeted molecules. Group means were compared using the nonparametric Kruskal-Wallis test, followed by the Dunn multiple comparisons tests (P < .05).
RESULTS
Patients With T1R Display a Distinct Metabolic Profile
Sera from patients with and those without T1R were analyzed by LC-MS in negative and positive ionization modes. A total of 3438 and 36 069 MFs (ie, metabolites defined by retention time and accurate mass) were detected in negative and positive ionization modes, respectively. MFs that met the filtering criteria were subjected to further analyses. When subjected to principal component analysis (PCA), LC-MS data collected in negative (1222 MFs) and positive (12 262 MFs) ion modes revealed clear separation between sera from patients with and those without T1R ( Figure 1A ). Data from patients S1 and S5 in the T1R group (Table 1) clustered with data from T1R-free patients in the PCA. There were no defining clinical characteristics (bacillary index, PGL-I serologic findings, or clinical form of leprosy) that could explain the PCA clustering of these 2 patients with T1R. It is noted that a higher percentage of patients with T1R were PGL-I positive (T1R group, 100%; T1R-free group, 33.33%; Table 1 ). This is in agreement with previous studies [25] . Statistical analyses of data from negative and positive ion modes identified 642 and 3525 MFs, respectively, with significantly altered abundances (P < .05; log 2 fold change ≥ 1.0) between patient groups ( Figure 1B and Supplementary Figure 1B ). Additionally, the majority (53.16%) of MFs with increased serum levels in the T1R group had log 2 fold changes ≥ 4.0. These data demonstrated that the metabolic profile of patients with T1R differed significantly from that of T1R-free patients.
PUFA Metabolism Is Altered in Patients With T1R
To identify changes in metabolic pathways in patients with T1R, 4167 MFs that differed significantly (P ≤ .05; log 2 fold change ≥ 1.0) between patients with and those without T1R were interrogated against the KEGG pathway database via the Pathos software tool [23] . Of the 4167 MFs, 173 had putative structural identifications and mapped to 40 KEGG pathways (Supplementary Table 2) . A large number (50) of the MFs mapped to PUFA metabolic pathways (AA, linoleic acid, α-linolenic acid, and biosynthesis of unsaturated fatty acids; Figure 1C ). Many compounds in these pathways have identical chemical formulas but are structurally distinct, based on sites of unsaturation, oxidation, or epoxidation; thus, 62% of the 50 MFs associated with PUFA metabolism were putatively assigned to ≥2 products (Supplementary Table 3 ). Nevertheless, the data indicated that lipid mediators derived from n-3 PUFAs (α-linolenic acid) and n-6 PUFAs (linoleic acid metabolism and AA metabolism) were highly altered in individuals with T1R. Interrogation of the Metlin database [24] Table 4 ). RvD1 has been previously associated with leprosy [13] . Eight additional metabolic pathways had relatively large numbers of putatively identified metabolites that significantly differed (P ≤ .05; log 2 fold change ≥1.0) between sera from the T1R and T1R-free groups ( Figure 1C and Supplementary Table 2 ).
Validation of Putatively Identified Lipid Mediators Altered in Patients
With T1R
The strong alignment of T1R-dysregulated MFs to PUFA metabolism led us to validate the structural identities and quantify a number of these products. Specifically, putatively identified metabolites known to act as proinflammatory or proresolving lipid mediators in mycobacterial diseases (LTB 4 , LXA 4 , PGD 2 , PGE 2 , and RvD1) [13, 15, 16, 26, 27] were targeted for comparison of MS/MS fragmentation patterns and retention times against authentic standards and MS/MS spectra in the Metlin library [24] . The precursors of these lipid mediators (AA, eicosapentaenoic acid [EPA], and docosahexaenoic acid [DHA]) were also targeted. Structural confirmation was achieved with high confidence for all of these products except the PGs and RvD1 (Figure 2A-D and Table 2 ). LXA 4 was detected in sera but at levels insufficient to provide reliable MS/MS fragmentation. Nevertheless, the putatively identified LXA 4 in sera shared the same retention time as the corresponding standard (Table 2) . Relative quantification of LTB 4 and LXA 4 , based on MS data, demonstrated increased levels of these lipid mediators in sera from the T1R group (Table 2 ). The biosynthesis of these products depends on the availability of free AA. The increased AA levels in sera from patients with T1R was modest but significant (1.2 log 2 fold change; P = .02; Table 2 ). Similar increases in the precursors of n-3 lipid mediators (EPA and DHA) were observed for sera from the T1R group. These data provided evidence that patients with T1R present dysregulation not only in the end products of n-6 PUFA metabolism, but also in the corresponding level of the AA precursor. The increased EPA and DHA levels indicated an alteration in proresolving lipid mediators levels during T1R (Supplementary Table 4 ).
EIAs Confirm LC/MS Data and Reveal a Reciprocal Change in Proinflammatory Versus Proresolving Lipid Mediators in T1R
To establish an independent line of evidence that T1R correlates with an alteration of lipid mediator metabolism and to further investigate whether RvD1, PGD 2 , and PGE 2 levels also changed, EIAs for selected lipid mediators were performed using the same sera subjected to LC-MS (Figures 3 and 4) and confirmed that LTB 4 and LXA 4 levels were increased in sera from patients with T1R ( Figure 3A and 3B, respectively) . The largest change was observed for LTB 4 , with fold changes of 5.4 and 15.6 as compared to values for T1R-free patients and healthy controls, respectively ( Figure 3A) . The increased level of LXA 4 in T1R sera was Table 1 . B, A graph of the number of MFs significantly altered in patients with T1R versus patients without T1R, plotted against the fold change in log 2 relative abundance. The y-axis is in log 10 scale. The total number of MFs with a higher abundance in patients with T1R are represented by the solid and checkered bars for negative and positive ion mode data, respectively. For more details, see Supplementary Table 1 . The total number of MFs with a lower abundance in patients with T1R are represented by the open and dotted bars for negative and positive ion mode data, respectively. C, Dysregulated MFs in patient with versus those without T1R were searched on the basis of their accurate mass against the KEGG database (available at: http://www.genome.jp/kegg/), using Pathos (available at: http://motif.gla.ac.uk/ Pathos/). The numbers of putatively identified MFs (y-axis) were plotted against the pathway to which they were assigned (x-axis). The total number of metabolites in each pathway is indicated in parentheses. statistically significant but more modest (1.2-fold as compared to both T1R-free patient and healthy control sera; Figure 3B ). Consequently, the LXA 4 to LTB 4 ratio was 3.88-fold and 10.29-fold lower in patients with T1R when compared with T1R-free and healthy controls, respectively (Supplementary Figure 1) . The level of the n-3 PUFA-derived lipid mediator RvD1 in sera from the T1R group was reduced by 3.7 fold as compared to the value for T1R-free patient sera, reaching levels that were similar to those of healthy controls ( Figure 3C) . Additionally, the RvD1/LTB 4 ratio observed in patients with T1R was decreased 25.5 and 6.99 fold as compared with T1R-free and healthy controls, respectively (Supplementary Figure 1) . PGD 2 and PGE 2 displayed dichotomous abundance changes ( Figure 4A and 4B, respectively). Most significantly, PGD 2 levels increased >2-fold in patients with T1R, compared with levels for T1R-free patients and healthy controls ( Figure 4A ). In contrast, PGE 2 levels were increased in T1R-free patient sera as compared to levels in sera from patients with T1R and healthy controls ( Figure 4B ). It was noted that patients S1 and S5 from the T1R group, who were outliers on the basis of PCA clustering, had levels of LTB 4 similar to those of T1R-free patients. However, this trend was not seen with other lipid mediators or for the RvD1 to LTB 4 ratio.
DISCUSSION
The pathogenesis of T1R in patients with leprosy is strongly associated with a Th1-mediated inflammatory response, characterized by the influx of CD4 + and Th17 cells, and an increase in levels of proinflammatory cytokines (interferon γ [IFN-γ], IFN-inducible protein 10, tumor necrosis factor α [TNF-α], and interleukin 6 [IL-6]) [4, 5, 7] . Recently, Mayboroda et al [28] demonstrated different urinary metabolic profiles in patients with leprosy at the time of T1R diagnosis. Our work adds to the understanding of T1R by identifying multiple host metabolic pathways that are altered in patients with T1R and leprosy, compared with T1R-free patients with leprosy. Most important was the alteration of PUFA metabolism, leading to a complex set of proinflammatory and proresolving lipid mediators with activities that are dependent on their location and cell type of origin and on the receptors they bind [29] . Previous metabolomics analyses of different clinical forms of T1R-free patients with leprosy revealed altered levels of various lipid mediators [12, 13] , and the level of gene transcription for a central enzyme in PUFA metabolism (COX-2) was increased in patients with leprosy and T1R [9, 30] . Thus, a T1R-associated change in the lipid mediator levels was not unexpected; however, the pattern and direction of abundance change provided a link between metabolic and cellular responses that lead to T1R-associated pathology. Data presented here demonstrated that patients with T1R had a significant increase in the abundance of LTB 4 , LXA 4 , and PGD 2 , while PGE 2 levels were decreased. All of these products are derived from AA ( Figure 5) . However, only a modest increase in AA levels was observed in patients with T1R. This indicated that increased AA levels are quickly shunted to PG biosynthesis via COX-1 and COX-2 or to lipoxin and leukotriene formation via 5-lipoxygenase (5-LO), 12-LO, and 15-LO [29] . The highly increased LTB 4 level and modest increase in the LXA 4 level observed in patients with T1R would indicate an enhanced AA metabolism via 5-LO resulting in LTA 4 and subsequent transformation to LTB 4 by leukotriene A 4 hydrolase or to LXA 4 via 12-LO or 15-LO [29] . LTB 4 is a potent proinflammatory lipid mediator that enhances Th1 responses, as well as IFN-γ and TNF-α production [17] , and subsequent generation of nitric oxide (NO) by macrophages [31] . This is consistent with high levels of TNF-α, IFN-γ, and NO levels reported in patients with leprosy with T1R [4, 5] . Furthermore, LTB 4 promotes migration of Th17 as well as CD4 + Th1 cells [32, 33] , and recent studies indicated an involvement of Th17 cells in T1R a The observed m/z values and RTs are for the commercial standards used to identify the targeted metabolite in pooled sera. All products in this table were evaluated in the negative ion mode.
b RT standard denotes that the metabolite in the pooled sera shared the same RT value with the corresponding commercial standard and the commercial standard when spiked in pooled sera. MS/MS denotes that the MS/MS spectra obtained from the compound in the pooled sera presented the same MS/MS fragmentation pattern obtained from the commercial standard, as well as MS/MS spectra in the Metlin database.
c The change in the relative abundance (peak area calculated by XCMS software) of each compound was considered statistically significant when P was < .05 and the log 2 fold change was ≥1.0. A positive log 2 fold change value refers to an increase in the abundance of the lipid mediator in patients with T1R.
[ [5] [6] [7] . Thus, LTB 4 may increase the Th17 response in individuals with T1R, as well as Th1-mediated inflammation ( Figure 5 ). The increased level of LXA 4 (a proresolving lipid mediator) in patients with T1R seems contrary to the strong Th1 response associated with T1R. However, the increase in LXA 4 was much less than that of LTB 4 . Notably the increase in LTB 4 was 4.5 times greater than that of LXA 4 , as measured by EIA. LTB 4 and LXA 4 production are associated with 5-LO activity localized to the nucleus and cytoplasm of leukocytes, respectively [34] . Thus, an increased level of 5-LO phosphorylation, as well as nuclear localization, would be expected in patients with T1R. A modest increase in LXA 4 levels might represent a mechanism by which patients with T1R are responding in a manner to attenuate increased inflammation (decreasing IFN-γ, IL-6, and TNF-α levels [26, 35] , as well as the Th1 response [15] ) and tissue damage ( Figure 5 ). LXA 4 and LTB 4 have opposing roles in the inflammation [36, 37] and an imbalance in the ratio of proresolving to proinflammatory mediators may better reflect the inflammatory status of an individual [38] . Thus, a lower LXA 4 to LTB 4 ratio in patients with T1R may suggest disequilibrium toward a proinflammatory response. The levels of prostaglandins (PGs) are altered in patients with type 1 reaction (T1R). Sera were examined for the levels of PGD 2 (A) and PGE 2 (B), using an enzyme immunoassay. Scatterplots show the individual value for each patient's sample, as well as the mean and standard deviation for each group. Group comparisons were evaluated with Kruskal-Wallis nonparametric analysis of variance and the Dunn multiple-range post hoc test. P values of >.05 are not shown. Red triangles represent patients S1 and S5 from the T1R group, whose values grouped together with those of T1R-free patients by principal component analysis ( Figure 1A ). The schematic indicates lipid mediators or enzymes with levels that were increased (red) or decreased (blue) in the patients with leprosy who had T1R. Bold products are those identified as altered in the current study. Enzyme names that are italicized were found at increased levels in patients with T1R in previous studies [9, 30] . In patients with T1R-free leprosy, an increased level of resolvin D1 (RvD1) occurs, which may lead to the inhibition of 5-lipoxygenase (5-LO) localization to the nuclear membrane and repression of leukotriene B 4 (LTB 4 ) and proinflammatory cytokine production. In patients with T1R, the significant decrease in RvD1 level may allow an increased nuclear membrane localization of 5-LO. This localization, along with an increase in arachidonic acid (AA) level, allows for increased LTB 4 production and induction of proinflammatory cytokines and a T-helper type 1 (Th1) response. Thus, this pathway is hypothesized to be a major factor in the development of T1R. Although lipoxin A 4 (LXA 4 ) can negatively regulate proinflammatory responses, the effects of LTB 4 in patients with T1R would predominate over those LXA 4 because of the higher concentration of LTB 4 . The elevated levels of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in patients with T1R do not seem to influence RvD1 production. Thus, we hypothesize that the increase in levels of these precursors reflects a decreased level or inhibition of the enzymes leading to RvD1. In parallel, an increase in prostaglandin (PG) D 2 (PGD 2 ) level and a decrease in PGE 2 level in patients with T1R may reflect the competition for a shared precursor, PGH 2 . Alternatively, increased PGD 2 production may result from an influx of mast cells, while decreased PGE 2 production might result from increased degradation via 15-dihydroxyprostaglandin dehydrogenase . Further studies are required to understand the kinetics of PG production and degradation during T1R development and the role of these lipid mediators in the pathology of T1R. Abbreviations: IL-6, interleukin 6; IFN-γ, interferon γ; TNF-α, tumor necrosis factor α.
The metabolism of n-3 PUFAs results in the formation of multiple proresolving lipid mediators [10] . Levels of the common precursors of the n-3 lipid mediators (EPA and DHA) were slightly increased in patients with T1R, as measured by MS. In contrast, the level of the downstream proresolving lipid mediator RvD1 was reduced 3.7-fold in sera from patients with T1R, compared with findings for T1R-free patients. Since RvD1 activity inhibits the formation of LTB 4 [34] , a significantly reduced RvD1 to LTB 4 ratio in patients with T1R indicated a lipid mediator imbalance in favor of the LTB 4 proinflammatory activity. These data suggest that the production of D-series resolvins in patients with T1R is not being driven by the amount of free DHA, but by the activity of LO enzymes (15-LO and 5-LO) [39] . More specifically, as patients with T1R present an increase in 5-LO-dependent production of LXA 4 and LTB 4 , it is plausible that the decreased production of RvD1 is due to lower activity or expression of 15-LO ( Figure 5 ). Further studies are needed to fully understand the role of LO enzymes in individuals with T1R and leprosy.
Multiple laboratories have shown that RvD1 production results in reduced levels of proinflammatory cytokines such as TNF-α, IL-6, and IFN-γ [14, 40] . Fredman et al [34] demonstrated that RvD1 modulates the phosphorylation and nuclear localization of 5-LO, resulting in decreased levels of LTB 4 . Thus, it is possible that a reduced RvD1 level in patients with T1R allows for the inverse shift in LTB 4 abundance and may be a factor in T1R pathogenesis ( Figure 5 ).
The activity of COX-1 and COX-2 on AA results in the formation of PGH 2 that serves as an intermediate substrate for functional PGs (eg, PGE 2 and PGD 2 ) [29] . Previous studies indicated a higher expression of COX-2 in individuals with T1R [9, 30] , but studies to evaluate PGD 2 and PGE 2 levels have not been performed. A quantitative assessment of PGE 2 and PGD 2 levels by EIA in patients with T1R demonstrated that PGD 2 levels were increased in patients with leprosy and T1R as compared to T1R-free patients with leprosy but that PGE 2 levels decreased. This modulation during T1R is likely a result of differential expression or regulation of PGD and PGE synthases ( Figure 5 ). PGD 2 production also occurs in mast cells [29] and, through its interaction with PGD 2 receptor 2, has been shown to recruit inflammatory cells [29] . Mast cells accumulate in skin lesions of patients with leprosy and are hypothesized to play a role in pathogenesis [41] . However, conflicting reports make it unclear whether mast cell numbers increase in lesions of patients with T1R [42, 43] . The observed increase in PGD 2 levels in patients with T1R underpins the need for further studies to investigate the role of mast cells in T1R-associated tissue damage ( Figure 5 ). Moreover, the increased level of PGD 2 in patients with T1R was unexpected, since this lipid mediator is known to inhibit a Th1 function but promote production of proinflammatory cytokines from Th2 cells [11] . It is possible that increased PGD 2 production occurs in patients with leprosy and T1R as a response to counter the increased Th1-mediated inflammation ( Figure 5 ). Further studies are required to address the function and source of PGD 2 associated with T1R in patients with leprosy. PGE 2 levels are tightly controlled by the expression of PGE synthase and 15-dihydroxyprostaglandin dehydrogenase (15-PGDH) that rapidly degrades PGE 2 in vivo [44] . Thus, low PGE 2 levels during T1R possibly result from higher expression or activity of 15-PGDH ( Figure 5) . Alternatively, increased expression of PGD synthase could compete with PGE synthase for PGH 2 ( Figure 5 ) [45] . Studies indicate that PGE 2 has an immunosuppressive role in leprosy [16, 27] . Moreover, it has been shown that patients with LL produce higher PGE 2 levels [13] , and this correlates with a decreased Th1 response. Therefore, decreasing of PGE 2 levels is expected to favor a heightened Th1 response in individuals with T1R ( Figure 5) .
The current study provides strong evidence that lipid mediators are associated with T1R pathogenesis, but it does not allow us to conclude whether they are a trigger or an outcome of the T1R event. This could only be determined with longitudinal studies and larger sample numbers. Further, the current study does not evaluate the production of enzymes required for lipid mediator formation or the level of lipid mediator receptors; this would require prospectively collected blood and tissue samples. Patients with leprosy who were receiving multidrug therapy were excluded from the study, to avoid potential metabolic alterations, since multidrug therapy may influence lipid metabolism [46, 47] . This resulted in a small sample size because T1R occurs more frequently during multidrug therapy [3] . Thus, the influence of multidrug therapy on lipid mediator levels during T1R needs to be evaluated in separate studies.
Our findings may allow for the development of tools for early diagnosis of T1R, thus decreasing the number of patients with a misdiagnosis and preventing nerve injuries and deformities. Longitudinal studies are underway to investigate whether LTB 4 , RvD1, and/or PGD 2 will serve as prognostic T1R biomarkers. It is also interesting to speculate whether targeting lipid mediator effects via inhibitors of LTB 4 synthesis [48] , antagonists of LTB 4 receptors [49] , or LXA 4 and RvD1 analogues [50] would allow for alternative treatments for T1R.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Notes
